5′-NT及其与ALT联合检测在鉴别ALP升高的恶性肿瘤骨转移中的价值

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (641 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the value of serum 5′-nucleotidase (5′-NT) and its combination with alanine aminotransferase (ALT) in identifying bone metastases in cancer patients with elevated alkaline phosphatase (ALP). Methods A total of 176 cancer patients who enrolled from Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College from December 2018 to August 2019 were selected. Among them, 88 cases with elevated ALP but without bone metastasis were named the liver cancer with elevated ALP group; other 88 cases with bone metastasis and elevated ALP but normal liver function were named the cancer with bone metastasis and elevated ALP group; 50 healthy volunteers were named the normal control group at the same time. The levels of serum 5′-NT and ALT were detected in three groups. Results The positive rate of 5′-NT in the liver cancer with elevated ALP group was higher than that in the cancer with bone metastasis and elevated ALP group (P < 0.01). The serum levels of 5′-NT in liver cancer with elevated ALP group were higher than those in the cancer with bone metastasis and elevated ALP group and the normal control group (P < 0.01). The increased serum 5′-NT or ALT levels were protective factors for bone metastases in cancer patients with elevated ALP. The area under the curve (AUC) of 5′-NT to judge the elevation of ALP to malignant tumor bone metastasis was 0.966, and the sensitivity was 90.91% and the specificity was 89.77% when the critical value was < 5.6 U/L. The AUC of 5′-NT combined with ALT was 0.980, and the specificity was increased to 96.49%. Conclusion The combined detection of 5′-NT and ALT has a certain clinical value in differentiating bone metastases of malignant tumors with elevated ALP.

Key words： 5′-nucleotidase Alkaline phosphates Cancer Bone metastases

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CUI Chanjuan GAO Jia LI Jia YU Mengyao ZHANG Hao CUI Wei▲

Cite this article:

CUI Chanjuan GAO Jia LI Jia YU Mengyao ZHANG Hao CUI Wei▲. The value of serum 5′-nucleotidase and its combination with alanine aminotransferase in identifying bone metastases in cancer patients with elevated ALP[J]. 中国医药导报, 2020, 17(17): 109-112.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I17/109

[1] 府伟灵，徐克前.临床生物化学检验[M].北京：北京人民卫生出版社，2013.
[2] Cortini M，Baldini N，Avnet S. New Advances in the Study of Bone Tumors：A Lesson from the 3D Environment [J]. Front Physiol，2019，10：814.
[3] Lang J，Zhao Q，He Y，et al. Bone turnover markers and novel biomarkers in lung cancer bone metastases [J]. Biomarkers，2018，23（6）：518-526.
[4] Demers LM，Costa L，Lipton A. Biochemical markers and skeletal metastases [J]. Cancer，2000，88（12 Suppl）：2919-2926.
[5] Xin Y，Han B，Lou J，et al. Diagnostic value of bone metabolic markers ICTP and BAP in lung cancer patients with bone metastases [J]. Zhongguo Fei Ai Za Zhi，2010， 13（10）：947-953.
[6] Castoldi E，Cappella A，Gibelli D，et al. The Difficult Task of Diagnosing Prostate Cancer Metastases on Dry Bone [J]. J Forensic Sci，2018，63（3）：672-682.
[7] Pinski J，Dorff TB. Prostate cancer metastases to bone：pathophysiology，pain management，and the promise of targeted therapy [J]. Eur J Cancer，2005，41（6）：932-940.
[8] Costa L，Demers LM，Gouveia-Oliveira A，et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status [J]. J Clin Oncol，2002，20（3）：850-856.
[9] Yang M，Liu C，Yu X. Skeletal-related adverse events during bone metastasis of breast cancer：current status [J]. Discov Med，2019，27（149）：211-220.
[10] Wang S，Li GX，Tan CC，et al. FOXF2 reprograms breast cancer cells into bone metastasis seeds [J]. Nat Commun，2019，10（1）：2707.
[11] Quayle L，Ottewell PD，Holen I. Bone Metastasis：Molecular Mechanisms Implicated in Tumour Cell Dormancy in Breast and Prostate Cancer [J]. Curr Cancer Drug Targets，2015，15（6）：469-480.
[12] Gowda S，Desai PB，Hull V，et al. A review on laboratory liver function tests [J]. Pan Afr Med J，2009， 3：17.
[13] Hyder MA，Hasan M，Mohieldein A. Comparative Study of 5′-Nucleotidase Test in Various Liver Diseases [J]. J Clin Diagn Res，2016，10（2）：BC01-BC03.
[14] Raghavendra DS，Rao SB. Studies on some serum enzyme levels in various liver diseases [J]. Indian J Clin Biochem，2000，15（1）：48-51.
[15] Fernandez NJ，Kidney BA. Alkaline phosphatase：beyond the liver [J]. Vet Clin Pathol，2007，36（3）：223-233.
[16] 伍建蓉，郑玲，杨红，等.血清骨型碱性磷酸酶对于恶性肿瘤骨转移的诊断价值[J]. 临床肿瘤学杂志，2010，15（11）：1007-1010.
[17] Woreta TA，Alqahtani SA. Evaluation of abnormal liver tests [J]. Med Clin North Am，2014，98（1）：1-16.
[18] Subhani TF，Nasar MA，Gupta RP，et al. Oxidative stress，antioxidant status and 5′-nucleotidase activity in chronic hepatitis c and alcoholic patients [J]. J Biomed Pharm Res，2015，4（1）：38-45.
[19] Shim JJ，Kim JW，Oh CH，et al. Serum alanine aminotransferase level and liver-related mortality in patients with chronic hepatitis B：A large national cohort study [J]. Liver Int，2018，38（10）：1751-1759.
[20] Sookoian S，Pirola CJ. Liver enzymes，metabolomics and genome-wide association studies：from systems biology to the personalized medicine [J]. World J Gastroenterol，2015，21（3）：711-725.